ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

March 25, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

April 30, 2022

Conditions

Epilepsy; Seizure

Interventions

DRUG

ES-481

28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period